Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-11-18 Sale | 2024-11-20 5:07 pm | Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer | 6,190 | $16.38 | $101,421 | 173,470 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-08-13 Exercise | 2024-08-14 6:03 pm | N/A 2030-02-24 | Contineum Therapeutics Inc. | CTNM | Huhn Stephen L. CMO & Sr VP, Clinical Dev. | 12,800 | $0 | 174,194 (Direct) | View |
| 2024-08-13 Exercise | 2024-08-14 6:03 pm | N/A N/A | Contineum Therapeutics Inc. | CTNM | Huhn Stephen L. CMO & Sr VP, Clinical Dev. | 12,800 | $1.01 | 174,194 (Direct) | View |
| 2024-06-24 Option Award | 2024-06-24 4:25 pm | N/A 2034-06-23 | Contineum Therapeutics Inc. | CTNM | Boyce Sarah Director | 29,500 | $0 | 29,500 (Direct) | View |
| 2024-06-03 Option Award | 2024-06-03 5:46 pm | N/A 2034-06-02 | Contineum Therapeutics Inc. | CTNM | Healy John Stephen General Counsel and Corp Sec | 160,000 | $0 | 160,000 (Direct) | View |
| 2024-05-24 Option Award | 2024-05-29 5:59 pm | N/A 2034-05-23 | Contineum Therapeutics Inc. | CTNM | Stengone Carmine N. CEO and President | 285,000 | $0 | 285,000 (Direct) | View |
| 2024-05-24 Option Award | 2024-05-29 5:58 pm | N/A 2034-05-23 | Contineum Therapeutics Inc. | CTNM | Slover Peter T Chief Financial Officer | 100,000 | $0 | 100,000 (Direct) | View |
| 2024-05-24 Option Award | 2024-05-29 5:58 pm | N/A 2034-05-23 | Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer | 103,700 | $0 | 103,700 (Direct) | View |
| 2024-05-24 Option Award | 2024-05-29 5:56 pm | N/A 2034-05-23 | Contineum Therapeutics Inc. | CTNM | Huhn Stephen L. CMO & Sr VP, Clinical Dev. | 100,000 | $0 | 100,000 (Direct) | View |
| 2024-05-24 Option Award | 2024-05-29 5:56 pm | N/A 2034-05-23 | Contineum Therapeutics Inc. | CTNM | Ignelzi Troy A. Director | 6,350 | $0 | 6,350 (Direct) | View |
| 2024-05-24 Option Award | 2024-05-29 5:55 pm | N/A 2034-05-23 | Contineum Therapeutics Inc. | CTNM | Ware Olivia C Director | 3,700 | $0 | 3,700 (Direct) | View |
| 2024-05-24 Option Award | 2024-05-29 5:54 pm | N/A 2034-05-23 | Contineum Therapeutics Inc. | CTNM | Lyons-Williams Lori Director | 29,500 | $0 | 29,500 (Direct) | View |
| 2024-05-24 Option Award | 2024-05-29 5:54 pm | N/A 2034-05-23 | Contineum Therapeutics Inc. | CTNM | Brady Todd R. Director | 29,500 | $0 | 29,500 (Direct) | View |
| 2024-05-24 Option Award | 2024-05-29 5:53 pm | N/A 2034-05-23 | Contineum Therapeutics Inc. | CTNM | Schimmelpennink Evert B. Director | 29,500 | $0 | 29,500 (Direct) | View |
| 2024-05-20 Option Award | 2024-05-20 7:00 pm | N/A 2034-05-19 | Contineum Therapeutics Inc. | CTNM | Ignelzi Troy A. Director | 23,150 | $0 | 23,150 (Direct) | View |
| 2024-04-09 Conversion | 2024-04-11 6:10 pm | N/A N/A | Contineum Therapeutics Inc. | CTNM | Versant Venture Capital VI L.P. Versant Ventures VI GP L.P. Versant Ventures VI GP-GP LLC Versant Vantage I L.P. Versant Vantage I GP L.P. Versant Vantage I GP-GP LLC Versant Venture Capital IV L.P. Versant Side Fund IV L.P. Versant Ventures IV LLC 10% Owner | 5,483,756 | $0 | 10,101,912 (Indirect) | View |
Ownership | 2024-04-10 5:05 pm | N/A N/A | Contineum Therapeutics Inc. | CTNM | JOHNSON & JOHNSON Johnson & Johnson Innovation - JJDC Inc. 10% Owner | 0 | $0 | 1,979,173 (Indirect) | View |
Ownership | 2024-04-04 9:22 pm | N/A N/A | Contineum Therapeutics Inc. | CTNM | Versant Venture Capital VI L.P. Versant Ventures VI GP L.P. Versant Ventures VI GP-GP LLC Versant Venture Capital IV L.P. Versant Side Fund IV L.P. Versant Ventures IV LLC Versant Vantage I L.P. Versant Vantage I GP L.P. Versant Vantage I GP-GP LLC 10% Owner | 0 | $0 | 5,316,663 (Direct) | View |
Ownership | 2024-04-04 5:59 pm | N/A 2034-03-26 | Contineum Therapeutics Inc. | CTNM | Ware Olivia C Director | 0 | $0 | 29,479 (Direct) | View |
Ownership | 2024-04-04 5:59 pm | N/A 2032-01-17 | Contineum Therapeutics Inc. | CTNM | Schimmelpennink Evert B. Director | 0 | $0 | 32,090 (Direct) | View |
Ownership | 2024-04-04 5:58 pm | N/A 2030-08-11 | Contineum Therapeutics Inc. | CTNM | Lyons-Williams Lori Director | 0 | $0 | 29,478 (Indirect) | View |
Ownership | 2024-04-04 5:56 pm | N/A 2034-03-26 | Contineum Therapeutics Inc. | CTNM | Brady Todd R. Director | 0 | $0 | 29,479 (Direct) | View |
Ownership | 2024-04-04 5:54 pm | N/A 2030-02-24 | Contineum Therapeutics Inc. | CTNM | Huhn Stephen L. CMO & Sr VP, Clinical Dev. | 0 | $0 | 236,725 (Direct) | View |
Ownership | 2024-04-04 5:52 pm | N/A 2030-10-05 | Contineum Therapeutics Inc. | CTNM | Slover Peter T Chief Financial Officer | 0 | $0 | 237,618 (Direct) | View |
Ownership | 2024-04-04 5:51 pm | N/A N/A | Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer | 0 | $0 | 670,865 (Direct) | View |
Ownership | 2024-04-04 5:49 pm | N/A N/A | Contineum Therapeutics Inc. | CTNM | Stengone Carmine N. CEO and President | 0 | $0 | 981,519 (Direct) | View |